“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy

We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy c...

Descripción completa

Detalles Bibliográficos
Autores principales: Janji, Bassam, Chouaib, Salem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437449/
https://www.ncbi.nlm.nih.gov/pubmed/34527430
http://dx.doi.org/10.1080/2162402X.2021.1968611
_version_ 1783752171002527744
author Janji, Bassam
Chouaib, Salem
author_facet Janji, Bassam
Chouaib, Salem
author_sort Janji, Bassam
collection PubMed
description We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.
format Online
Article
Text
id pubmed-8437449
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84374492021-09-14 “Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy Janji, Bassam Chouaib, Salem Oncoimmunology Author’s View We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients. Taylor & Francis 2021-09-07 /pmc/articles/PMC8437449/ /pubmed/34527430 http://dx.doi.org/10.1080/2162402X.2021.1968611 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Janji, Bassam
Chouaib, Salem
“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
title “Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
title_full “Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
title_fullStr “Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
title_full_unstemmed “Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
title_short “Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
title_sort “suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437449/
https://www.ncbi.nlm.nih.gov/pubmed/34527430
http://dx.doi.org/10.1080/2162402X.2021.1968611
work_keys_str_mv AT janjibassam suffocatingtumorsbyblockingadaptationtohypoxiaanewheadwayinmelanomaimmunotherapy
AT chouaibsalem suffocatingtumorsbyblockingadaptationtohypoxiaanewheadwayinmelanomaimmunotherapy

Ejemplares similares